- Positive results achieved from the phase 3 MAESTRO-NAFLD-1 study using resmetirom to treat patients with NASH. Nearly half of patients in 100 mg dose arm achieved 50% reduction liver fat.
- Key study will be MAESTRO-NASH, which will have liver biopsy data. Results for this study expected later in 2022.
- A second THR beta agonist drug is being developed for patients with NASH/Hyperlipidemia known as MGL-3745, but is only in preclinical testing.
- Even with meeting endpoints and successful liver biopsy data from MAESTRO-NASH, it will ultimately be up to the FDA to determine if risk-benefit profile warrants regulatory approval.
For further details see:
Madrigal NASH Data Is Promising, Next Study Is Key For Success